Allarity Therapeutics, Inc. Financing Receivable Modification To Total Financing Receivables Percent
Allarity Therapeutics, Inc. (ALLR) reported Financing Receivable Modification To Total Financing Receivables Percent of 10.00% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-08.
Discontinued › Notes › and Others
us-gaap:FinancingReceivableModificationToTotalFinancingReceivablesPercent · last filed 2024-03-08
- Allarity Therapeutics, Inc. financing receivable modification to total financing receivables percent for fiscal 2023 was 10.00%.
| Period end | Financing Receivable Modification To Total Financing Receivables Percent 12 month |
|---|---|
| 2023-12-31 | 10.00% 10-K · filed 2024-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |